Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial

[1]  C. Franzius,et al.  Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method , 2020, The Journal of Nuclear Medicine.

[2]  Sonali M. Smith,et al.  Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Rosenwald,et al.  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial , 2019, The Lancet.

[4]  R. Boellaard,et al.  Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. , 2019, European journal of cancer.

[5]  A. Rosenwald,et al.  Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome , 2019, Blood Cancer Journal.

[6]  H. Eltzschig,et al.  Hypoxia signaling in human diseases and therapeutic targets , 2019, Experimental & Molecular Medicine.

[7]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[8]  Darrin W. Byrd,et al.  Test–Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network , 2018, The Journal of Nuclear Medicine.

[9]  E. Meylan,et al.  Glucose transporters in cancer – from tumor cells to the tumor microenvironment , 2018, The FEBS journal.

[10]  W. Klapper,et al.  Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Messmann,et al.  Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic , 2017, npj Precision Oncology.

[12]  Chengwu Tang,et al.  Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer , 2017, Oncotarget.

[13]  A. Scaloni,et al.  APE1 polymorphic variants cause persistent genomic stress and affect cancer cell proliferation , 2016, Oncotarget.

[14]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Russo,et al.  Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research , 2013, Journal of experimental & clinical cancer research : CR.

[16]  C. Qin,et al.  The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  H. Eom,et al.  VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma , 2010, Cancer science.

[18]  J. Ingels,et al.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer , 2012, Breast Cancer Research.

[19]  Pu Li,et al.  Genetic polymorphisms in APE1 are associated with renal cell carcinoma risk in a Chinese population , 2011, Molecular carcinogenesis.

[20]  C. Hellerbrand,et al.  Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma , 2011, Molecular membrane biology.

[21]  C. Langner,et al.  Single nucleotide polymorphisms in the hypoxia‐inducible factor‐1 gene and colorectal cancer risk , 2010, Molecular carcinogenesis.

[22]  R. Kimmig,et al.  The XbaI G>T Polymorphism of the Glucose Transporter 1 Gene Modulates 18F-FDG Uptake and Tumor Aggressiveness in Breast Cancer , 2010, The Journal of Nuclear Medicine.

[23]  Seong-Jang Kim,et al.  Open Access RESEARCH , 2010 .

[24]  R. Gascoyne,et al.  Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Freimanis,et al.  Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. , 2008, Carcinogenesis.

[26]  Xihong Lin,et al.  VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Eisen,et al.  Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. , 2007, Human molecular genetics.

[28]  J. Cerhan,et al.  Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. , 2006, Blood.

[29]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[30]  U. Langsenlehner,et al.  The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake , 2004, Breast Cancer Research and Treatment.

[31]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[32]  L. Poellinger,et al.  Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. , 2003, Carcinogenesis.